The overall objective of this proposal is to validate the potential of noninvasive magnetic resonance imaging (MRI) and spectroscopy (MRS) to monitor disease progression and to serve as an outcome measure for clinical trials in muscular dystrophies. Duchenne muscular dystrophy (DMD) is one of the most devastating genetically linked neuromuscular diseases and is characterized by the absence of dystrophin, resulting in progressive muscle weakness, loss of walking ability and premature death. Despite the poor prognosis therapeutic interventions have been lacking, and outcome measures for clinical trials have been limited to measures of muscle function, quality of life, serum biomarkers of muscle breakdown and invasive muscle biopsies. Closely related to DMD, Becker muscular dystrophy (BMD) has also been largely neglected in therapeutic development, due to its heterogeneity, small patient population, lack of outcome measures and uncertainty surrounding the patterns of disease progression, which may be mutation-dependent. Additional quantitative outcome measures that are noninvasive and sensitive to changes in muscle structure and composition are needed to facilitate the rapid translation of promising new interventions from preclinical studies to clinical trials in both forms of muscular dystrophy. As such, this project targets the development and validation of magnetic resonance as a noninvasive biomarker of disease progression in muscular dystrophy. Using a multi-site research design this study will characterize the intramuscular lipid content, cellular muscle damage and contractile area in the lower and/or upper extremity muscles of 200 ambulatory or non-ambulatory boys/men with DMD, 105 ambulatory or non-ambulatory men with BMD, and 110 healthy age matched boys/men using a combination of sophisticated MRI and MRS technologies. The trunk and respiratory muscles will be characterized in a subgroup of subjects (80 DMD, 20 BMD and 10 controls). In order to assess the sensitivity of each MR measure individually as well as composite MR measures (combination of muscles) to disease progression, all boys/men with DMD or BMD will be re-evaluated in yearly or 6 month intervals. The predictive outcome value of MRI/MRS will be further evaluated by determining the relationship between changes in MR measures and loss in muscle strength and/or functional ability. Using MRI/MRS we will also examine the effect of initiating corticosteroid treatment on skeletal muscle characteristics and composition. Examination of muscles in BMD patients will allow us to increase our understanding of how much dystrophin is needed to protect the muscle. To this end we will specifically examine the relationship between the MR phenotype (e.g. fast or slow increases in fat fraction) and dystrophin mutations, dystrophin expression and other histological markers. Finally, to ensure the rigor of this study we will examine the day-day reproducibility, inter MR system reproducibility and inter-validate the MR measures using localized MRS (golden standard). We anticipate that the MR techniques developed and validated in this study will be suitable for clinical trials in a wide range of muscular dystrophies and other neuromuscular diseases. In addition, MR characterization may serve as a powerful tool to further advance our understanding of the pathogenesis of muscular dystrophy and help guide the design of future trials.

Explore Clinical Trials

Select and Apply Filters

Showing 39 clinical trials

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

Actively Recruiting
4 Years to <9 Years
Restoring or Replacing Dystrophin
Actively Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - Excluding any deletion of exon 8 and/or 9
Industry/Sponsor: Sarepta Therapeutics, Inc.
Ambulation: Ambulatory
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT06597656
Location: United States
Next Steps:

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Actively Recruiting
0 Years to <18 Years
Restoring or Replacing Dystrophin
Actively Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - Any deletion in exons 1 to 11 or 42 to 45 are excluded
Industry/Sponsor: Solid Biosciences Inc.
Ambulation: Varies by cohort
Steroid Use: Cohorts 1,2,4,&5 - Stable course of steroids; Cohort 3 - N/A
Eligible Sexes: Male
Clinical Trial NCT ID: NCT06138639
Next Steps:

A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy

Actively Recruiting
8 Years to <18 Years
Enhancing Bone Health
Actively Recruiting
Therapeutic Approach: Enhancing Bone Health
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Hoffmann-La Roche
Ambulation: Group 1 - No specific requirement, Group 2 - Ambulatory
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT06450639
Next Steps:

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

Actively Recruiting
2 Years to <5 Years
Restoring or Replacing Dystrophin
Actively Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - variants in exons 18 to 58
Industry/Sponsor: Insmed Gene Therapy LLC
Ambulation: Ambulatory
Steroid Use: No specific requirement
Eligible Sexes: Male
Clinical Trial NCT ID: NCT06817382
Location: United States
Next Steps:

AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Boys With DMD

Actively Recruiting
0 Years to <12 Years
Observational
Actively Recruiting
Therapeutic Approach: Observational
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: REGENXBIO Inc.
Ambulation: No specific requirement
Steroid Use: No specific requirement
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05683379
Location: United States
Next Steps:

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Actively Recruiting
1 to <12 years
Restoring or Replacing Dystrophin
Actively Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - Part 1: Excluding variants in exons 1-17, Part 2 and 3: Excluding deletions or point mutations in exons 8, 9, and/or 10
Industry/Sponsor: REGENXBIO Inc.
Ambulation: Ambulatory
Steroid Use: Varies by cohort and age
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05693142
Next Steps:

An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy

Actively Recruiting
4+ Years
Restoring or Replacing Dystrophin
Actively Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - Excluding any deletion of exon 8 and/or 9
Industry/Sponsor: Sarepta Therapeutics, Inc.
Ambulation: No specific requirement
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT06270719
Location: United States
Next Steps:

Assessment of Neurodevelopmental Needs in Duchenne Muscular Dystrophy

Actively Recruiting
3+ Years
Observational
Actively Recruiting
Therapeutic Approach: Observational
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Virginia Commonwealth University
Ambulation: No specific requirement
Steroid Use: No specific requirement
Eligible Sexes: All
Clinical Trial NCT ID: NCT05280730
Location: United States
Next Steps:

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

Actively Recruiting
5+ Years
Observational
Actively Recruiting
Therapeutic Approach: Observational
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Columbia University
Ambulation: Ambulatory
Steroid Use: Stable course of steroids
Eligible Sexes: All
Clinical Trial NCT ID: NCT06839469
Location: United States
Next Steps:

Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

Actively Recruiting
18+ Years
Regulating Calcium Balance
Actively Recruiting
Therapeutic Approach: Regulating Calcium Balance
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Sardocor Corp.
Ambulation: No specific requirement
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT06224660
Location: United States
Next Steps:

Molecular Analysis of Patients With Neuromuscular Disease

Actively Recruiting
All ages
Observational
Actively Recruiting
Therapeutic Approach: Observational
Variant Requirement: Diagnosis of a neuromuscular disorder for self or family member
Industry/Sponsor: Boston Children's Hospital
Ambulation: No specific requirement
Steroid Use: No specific requirement
Eligible Sexes: All
Clinical Trial NCT ID: NCT00390104
Location: United States
Next Steps:

NS-050/NCNP-03 in Boys With DMD (Meteor50)

Actively Recruiting
4 years to <15 years
Restoring or Replacing Dystrophin
Actively Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - amenable to exon 50 skipping
Industry/Sponsor: NS Pharma, Inc.
Ambulation: Ambulatory
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT06053814
Next Steps:

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

Actively Recruiting
4 Years to <15 Years
Restoring or Replacing Dystrophin
Actively Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - Amenable to exon 44 skipping
Industry/Sponsor: NS Pharma, Inc.
Ambulation: Ambulatory
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05996003
Location: United States
Next Steps:

Once Weekly Infant Corticosteroid Trial for DMD

Actively Recruiting
1 Month to 30 Months
Reducing Inflammation
Actively Recruiting
Therapeutic Approach: Reducing Inflammation
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Nationwide Children's Hospital
Ambulation: No specific requirement
Steroid Use: Steroid-naive
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05412394
Location: United States

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy.

Actively Recruiting
2+ Years
Observational
Actively Recruiting
Therapeutic Approach: Observational
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Catalyst Pharmaceuticals, Inc.
Ambulation: No specific requirement
Steroid Use: Currently on treatment with Vamorolone (AGAMREE)
Eligible Sexes: Male
Clinical Trial NCT ID: NCT06564974
Next Steps:

Trial of Cell Based Therapy for DMD

Actively Recruiting
18+ Years
Improving Muscle Growth & Protection
Actively Recruiting
Therapeutic Approach: Improving Muscle Growth & Protection
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: University of Minnesota
Ambulation: Non-ambulatory
Steroid Use: No specific requirement
Eligible Sexes: All
Clinical Trial NCT ID: NCT06692426
Location: United States
Next Steps:

Vasodilator and Exercise Study for DMD (VASO-REx)

Actively Recruiting
6+ Years
Improving Muscle Growth & Protection
Actively Recruiting
Therapeutic Approach: Improving Muscle Growth & Protection
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: University of Florida
Ambulation: Ambulatory
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT06290713
Location: United States

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Active, Not Recruiting
8 Years to 18+ Years
Restoring or Replacing Dystrophin
Active, Not Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - Excluding any deletion of exon 8 and/or 9
Industry/Sponsor: Sarepta Therapeutics, Inc.
Ambulation: Cohort 1 - Non-ambulatory; Cohort 2 - Ambulatory
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05881408
Next Steps:

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Active, Not Recruiting
2+ Years
Restoring or Replacing Dystrophin
Active, Not Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - variant criteria varies by cohort
Industry/Sponsor: Sarepta Therapeutics, Inc.
Ambulation: Varies by cohort
Steroid Use: Varies by cohort
Eligible Sexes: Male
Clinical Trial NCT ID: NCT04626674
Location: United States

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Active, Not Recruiting
10+ Years
Improving Muscle Growth & Protection
Active, Not Recruiting
Therapeutic Approach: Improving Muscle Growth & Protection
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Capricor Inc.
Ambulation: No specific requirement
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05126758
Location: United States
Next Steps:

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

Active, Not Recruiting
4 Years to <10 Years
Improving Muscle Growth & Protection
Active, Not Recruiting
Therapeutic Approach: Improving Muscle Growth & Protection
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Edgewise Therapeutics, Inc.
Ambulation: Ambulatory
Steroid Use: Cohorts 1,2,3,4,5 - Stable course of steroids; Cohort 2NS - No steroids within 6 months
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05540860
Location: United States
Next Steps:

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Active, Not Recruiting
18 Years to <65 Years
Reducing Inflammation
Active, Not Recruiting
Therapeutic Approach: Reducing Inflammation
Variant Requirement: Becker - in-frame mutation
Industry/Sponsor: ReveraGen BioPharma, Inc.
Ambulation: Ambulatory
Steroid Use: Not currently using
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05166109
Next Steps:

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (MIS51ON)

Active, Not Recruiting
4 Years to <14 Years
Restoring or Replacing Dystrophin
Active, Not Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - amenable to exon 51 skipping
Industry/Sponsor: Sarepta Therapeutics, Inc.
Ambulation: Ambulatory
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT03992430
Next Steps:

AAV9 U7snRNA Gene Therapy to Treat Boys With DMD Exon 2 Duplications.

Active, Not Recruiting
6 Months to <14 Years
Restoring or Replacing Dystrophin
Active, Not Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - Duplication exon 2
Industry/Sponsor: Nationwide Children's Hospital
Ambulation: Pre-ambulant (not yet walking) or ambulant
Steroid Use: Age 4 years+: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT04240314
Location: United States
Next Steps:

Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD

Active, Not Recruiting
18+ Years
Observational
Active, Not Recruiting
Therapeutic Approach: Observational
Variant Requirement: Known female carrier and/or mother of a child with Duchenne or Becker
Industry/Sponsor: Nationwide Children's Hospital
Ambulation: No specific requirement
Steroid Use: No current steroid treatment
Eligible Sexes: Female
Clinical Trial NCT ID: NCT02972580
Location: United States
Next Steps:

Defining Endpoints in Becker Muscular Dystrophy

Active, Not Recruiting
6+ Years
Observational
Active, Not Recruiting
Therapeutic Approach: Observational
Variant Requirement: Becker - Variant requirement varies by cohort
Industry/Sponsor: Virginia Commonwealth University
Ambulation: Varies by cohort
Steroid Use: No specific requirement
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05257473
Next Steps:

Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

Active, Not Recruiting
6+ Years
Improving Muscle Growth & Protection
Active, Not Recruiting
Therapeutic Approach: Improving Muscle Growth & Protection
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Italfarmaco
Ambulation: Ambulatory or non-ambulatory
Steroid Use: No specific requirement
Eligible Sexes: Male
Clinical Trial NCT ID: NCT03373968
Next Steps:

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

Active, Not Recruiting
4+ Years
Restoring or Replacing Dystrophin
Active, Not Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - Amenable to exon 53 skipping
Industry/Sponsor: NS Pharma, Inc.
Ambulation: No specific requirement
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT04687020
Next Steps:

Microdystrophin Gene Transfer Study in Adolescents and Children With DMD

Active, Not Recruiting
4 Years to <18 Years
Restoring or Replacing Dystrophin
Active, Not Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Solid Biosciences Inc.
Ambulation: Ambulatory for children, non-ambulatory for adolescents
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT03368742
Location: United States
Next Steps:

Open-label Extension of the HOPE-2 Trial

Active, Not Recruiting
10+ years
Improving Muscle Growth & Protection
Active, Not Recruiting
Therapeutic Approach: Improving Muscle Growth & Protection
Variant Requirement: Duchenne - excludes exon 44 skip-amenable or deletion of exons 3-7
Industry/Sponsor: Capricor Inc.
Ambulation: No specific requirement
Steroid Use: No specific requirement
Eligible Sexes: All
Clinical Trial NCT ID: NCT04428476
Location: United States
Next Steps:

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Active, Not Recruiting
7+ Years
Improving Heart Function
Active, Not Recruiting
Therapeutic Approach: Improving Heart Function
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Cumberland Pharmaceuticals
Ambulation: No specific requirement
Steroid Use: No specific requirement
Eligible Sexes: Male
Clinical Trial NCT ID: NCT03340675
Location: United States
Next Steps:

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping (EXPLORE44OLE)

Active, Not Recruiting
7 Years to <28 Years
Restoring or Replacing Dystrophin
Active, Not Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - Amenable to exon 44 skipping
Industry/Sponsor: Avidity Biosciences, Inc.
Ambulation: No specific requirement
Steroid Use: No specific requirement
Eligible Sexes: Male
Clinical Trial NCT ID: NCT06244082
Location: United States
Next Steps:

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Active, Not Recruiting
12 Years to <51 Years
Improving Muscle Growth & Protection
Active, Not Recruiting
Therapeutic Approach: Improving Muscle Growth & Protection
Variant Requirement: Becker - No specific requirement
Industry/Sponsor: Edgewise Therapeutics, Inc.
Ambulation: Ambulatory
Steroid Use: Not currently using
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05291091
Next Steps:

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy

Active, Not Recruiting
6 Years to <18 Years
Improving Muscle Growth & Protection
Active, Not Recruiting
Therapeutic Approach: Improving Muscle Growth & Protection
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Edgewise Therapeutics, Inc.
Ambulation: Ambulatory
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT06100887
Location: United States
Next Steps:

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Active, Not Recruiting
4 Years to <17 Years
Restoring or Replacing Dystrophin
Active, Not Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - amenable to exon 51 skipping
Industry/Sponsor: Dyne Therapeutics
Ambulation: Ambulatory or non-ambulatory <2 years
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05524883
Next Steps:

Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy

Active, Not Recruiting
2+ Years
Reducing Inflammation
Active, Not Recruiting
Therapeutic Approach: Reducing Inflammation
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: Children's National Research Institute
Ambulation: Ambulatory
Steroid Use: Steroid-naive
Eligible Sexes: Male
Clinical Trial NCT ID: NCT03936894
Location: United States
Next Steps:

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

Active, Not Recruiting
6 Years to <14 Years
Restoring or Replacing Dystrophin
Active, Not Recruiting
Therapeutic Approach: Restoring or Replacing Dystrophin
Variant Requirement: Duchenne - Amenable to exon 45 or 53 skipping
Industry/Sponsor: Sarepta Therapeutics, Inc.
Ambulation: Ambulatory
Steroid Use: Stable course of steroids
Eligible Sexes: Male
Clinical Trial NCT ID: NCT02500381
Next Steps:

Tadalafil as Adjuvant Therapy for DMD

Active, Not Recruiting
7 Years to <13 Years
Improving Muscle Growth & Protection
Active, Not Recruiting
Therapeutic Approach: Improving Muscle Growth & Protection
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: University of Florida
Ambulation: Ambulatory
Steroid Use: No specific requirement
Eligible Sexes: Male
Clinical Trial NCT ID: NCT05195775
Location: United States
Next Steps:

Twice Weekly Steroids and Exercise as Therapy for DMD

Active, Not Recruiting
5 Years to <10 Years
Reducing Inflammation
Active, Not Recruiting
Therapeutic Approach: Reducing Inflammation
Variant Requirement: Duchenne - No specific requirement
Industry/Sponsor: University of Florida
Ambulation: Ambulatory
Steroid Use: No specific requirement
Eligible Sexes: Male
Clinical Trial NCT ID: NCT04322357
Location: United States